Aura Biosciences (AURA) Set to Post Quarterly Earnings on Thursday

Key Points

• Aura Biosciences is expected to report Q3 2026 results before the market opens on November 5, with analysts forecasting a loss of $0.3681 per share. The earnings call is scheduled for November 11 at 9:30 a.m. ET.
• The company reported a larger-than-expected loss of $0.48 per share in its prior quarter, compared with the $0.38 consensus estimate. Analysts project full-year and next-year losses of $1.61 and $1.39 per share, respectively.
• Aura shares opened at $6.40, near their 50-day and 200-day moving averages, with a 52-week range of $4.73 to $9.53. Analyst sentiment is mixed, with an average “Hold” rating and a $17.50 price target, while Aura continues developing its lead cancer therapy, AU-011, for choroidal melanoma.

Aura Biosciences (NASDAQ:AURA - Get Free Report) is anticipated to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Aura Biosciences to announce earnings of ($0.3681) per share for the quarter. Interested persons can check the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 11, 2026 at 9:30 AM ET.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.10). On average, analysts expect Aura Biosciences to post ($1.61) EPS for the current fiscal year and ($1.39) EPS for the next fiscal year.

Aura Biosciences Stock Performance

NASDAQ:AURA opened at $6.40 on Thursday. The company has a market cap of $663.71 million, a price-to-earnings ratio of -3.66 and a beta of 0.41. The stock's fifty day moving average price is $6.74 and its two-hundred day moving average price is $6.68. Aura Biosciences has a 52-week low of $4.73 and a 52-week high of $9.53.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. HC Wainwright lowered their target price on Aura Biosciences from $24.00 to $18.00 and set a "buy" rating for the company in a research note on Tuesday, August 11th. Wall Street Zen lowered Aura Biosciences from a "hold" rating to a "sell" rating in a research note on Sunday, August 16th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Aura Biosciences in a research note on Monday, October 12th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $17.50.

About Aura Biosciences

Aura Biosciences, Inc NASDAQ: AURA is a clinical-stage biotechnology company developing targeted therapies for cancer. The company's platform is designed to use tumor-targeting virus-like particles to selectively bind to cancer cells and deliver therapeutic payloads, with the goal of treating tumors while limiting damage to surrounding healthy tissue.

Aura's lead product candidate is AU-011, also known as belzupacap sarotalocan, an investigational therapy being developed for primary choroidal melanoma, a form of eye cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.